信迪利单抗联合安罗替尼对晚期非小细胞肺癌患者血清肿瘤标志物、血管生成因子和NLR、PLR、LMR的影响  

Effect of Sintilimab Combined with Anlotinib on Serum Tumor Markers,Angiogenesis Factors,NLR,PLR and LMR in Patients with Advanced Non-Small Cell Lung Cancer

作　　者：韩尚 纪雅玲 王浩 张瑶 汪海岩 HAN Shang;JI Ya-ling;WANG Hao;ZHANG Yao;WANG Hai-yan(Department of Medical Oncology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,221000,China)

机构地区：[1]徐州医科大学附属医院肿瘤内科,江苏徐州221000

出　　处：《现代生物医学进展》2024年第19期3676-3678,共3页Progress in Modern Biomedicine

基　　金：江苏省卫健委高层次卫生人才"六个一工程"拔尖人才科研项目(LGY2020006)。

摘　　要：目的:探讨安罗替尼和信迪利单抗联合对晚期非小细胞肺癌(NSCLC)患者血清血管生成因子、肿瘤标志物和血小板/淋巴细胞比值(PLR)、中性粒细胞/淋巴细胞比值(NLR)、淋巴细胞/单核细胞比值(LMR)的影响。方法:根据随机数字表法将84例晚期NSCLC患者分为对照组(42例,安罗替尼治疗)和研究组(42例,信迪利单抗联合安罗替尼治疗)。对比两组疗效、血清肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)和癌胚抗原(CEA)]、血管生成因子[血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)]、NLR、PLR、LMR,观察两组不良反应发生率。结果:与对照组治疗后相比,研究组的客观缓解率、疾病控制率、LMR更高,VEGF、bFGF、CA125、CYFRA21-1、CEA、NLR、PLR更低(P<0.05)。两组不良反应发生率组间对比未见差异(P>0.05)。结论:联合应用安罗替尼以及信迪利单抗治疗晚期NSCLC患者,可降低肿瘤标志物水平、抑制NSCLC血管生成、减轻炎症反应。Objective:To investigate the effects of anlotinib combined with sintilimab on serum angiogenesis factors,tumor markers,platelet/lymphocyte ratio(PLR),neutrophil/lymphocyte ratio(NLR)and lymphocyte/monocyte ratio(LMR)in advanced non-small cell lung cancer(NSCLC)patients.Methods:84 advanced NSCLC patients were divided into control group(42 cases,treated with anlotinib)and study group(42 cases,treated with sintilizumab combined with anlotinib)according to the random number table method.The efficacy,serum tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)],angiogenesis factors[vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)],NLR,PLR,LMR were compared between two groups,the incidence of adverse reactions was observed.Results:Compared with control group post-treatment,the objective remission rate,disease control rate and LMR in study group were higher,and VEGF,bFGF,CA125,CYFRA21-1,CEA,NLR and PLR were lower(P<0.05).There was no difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion:Combined use of anlotinib and Sintilimab in the treatment of advanced NSCLC patients,which can reduce the level of tumor markers,inhibit NSCLC angiogenesis,and reduce inflammatory response.

关 键 词：信迪利单抗 安罗替尼 晚期非小细胞肺癌 肿瘤标志物 血管生成因子 NLR PLR LMR 

分 类 号：R734.2[医药卫生—肿瘤]